Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

How to use ETFs in your portfolio

Bell Direct
July 28, 2020

Morning Bell 28 July

Jessica Amir
July 28, 2020

Morning Bell 27 July

Jessica Amir
July 27, 2020

Weekly Wrap 24 July

Jessica Amir
July 24, 2020

Morning Bell 24 July

Paulina Peters
July 24, 2020

Morning Bell 23 July

Jessica Amir
July 23, 2020

Morning Bell 22 July

Jessica Amir
July 22, 2020

Morning Bell 21 July

Jessica Amir
July 21, 2020

Morning Bell 20 July

Jessica Amir
July 20, 2020

Weekly Wrap 17 July

Bell Direct
July 17, 2020

Morning Bell 17 July

Jessica Amir
July 17, 2020